EU H2020 Project "EYETREAT (Innovative tool for personalized treatment of patients with neovascular..)": description, partecipants, costs and EC-fundings

#	Pagina
attuale pagina	/open-h2020/projects/215767/index.html
-1	/open-h2020/projects/202690/deliverables.html
-2	/open-h2020/projects/215060/index.html
-3	/open-h2020/projects/218053/index.html

EyeTREAT project word cloud

Explore the words cloud of the EyeTREAT project. It provides you a very rough idea of what is the project "EyeTREAT" about.

life drug consists instance centre treatment models determinations intravitreal therapeutic benefit treatments technique eylea sectoral burden health renowned pharmacodynamic personalization amd linking consensus disciplinary scan combining retina candidate expertise 2040 thickness clear population imaging with clinics injection inter ocular vegf missing rest ophthalmic avastin definitely ball almost ageing first macular effect appropriate anticipated threatening optical central europeans pharmacokinetic individualized lasting coherence age quantitative constitute patient dosing frequency eye lucentis oct reducing intervals career computational individual patients regimen regular vitreous researcher dose anti pioneer tomography tool manchester care optimization quality visual efficient invasively character university tools illnesses varies 25 measuring degeneration clinical injections million

Project "EyeTREAT" data sheet

The following table provides information about the project.

Coordinator	THE UNIVERSITY OF MANCHESTER Organization address address: OXFORD ROAD city: MANCHESTER postcode: M13 9PL website: www.manchester.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Project website	https://www.research.manchester.ac.uk/portal/evamaria.delamo.html
Total cost	122˙159 €
EC max contribution	122˙159 € (100%)
Programme	1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
Code Call	H2020-MSCA-IF-2017
Funding Scheme	MSCA-IF-EF-ST
Starting year	2018
Duration (year-month-day)	from 2018-09-01 to 2019-11-30

#	participants	country	role	EC contrib. [€]
1	THE UNIVERSITY OF MANCHESTER	UK (MANCHESTER)	coordinator	122˙159.00

THE UNIVERSITY OF MANCHESTER

UK (MANCHESTER)

coordinator

122˙159.00

Project objective

With the ageing population, visual threatening illnesses are increasing. For instance, age-related macular degeneration (AMD) is expected to affect almost 25 million Europeans by 2040. The AMD treatment consists in regular injections of the anti-VEGF therapeutic drug (Lucentis, Avastin, Eylea) into the eye ball, vitreous, for the rest of the patient life. However, the dosing intervals varies widely among the patients and there is no a clear consensus or quantitative method for evaluating the injection frequency. For that, computational tools linking the drug dose regimen and the drug effect in the retina are needed. However, such pharmacokinetic-pharmacodynamic models are still missing. Combining population pharmacokinetic and optical coherence tomography (OCT) imaging technique is a new, novel and promising approach. The drug effect can be evaluated non-invasively, measuring the central macular thickness in the retina scan. The models generated will allow appropriate individualized dosing regimen to the patients in clinics that will be anticipated from individual retina scan determinations with OCT. The optimization and personalization of dosing regimen will ensure an efficient long-lasting treatment, improving patient quality of life while reducing the burden to the health care system. Moreover, the models will increase our understanding in the treatments, constitute a pioneer tool in effect assessment in ocular therapeutic field and a first step towards more advanced ophthalmic models. The candidate has strong expertise in intravitreal pharmacokinetic and this project will advance her into clinical pharmacodynamic modelling at the renowned Centre for Applied Pharmacokinetic Research, University of Manchester. The inter-disciplinary and inter-sectoral character of the project will definitely benefit her career development as a researcher.

Publications

List of publications.
year	authors and title	journal	last update
2019	Astrid Subrizi, Eva M. del Amo, Viktor Korzhikov-Vlakh, Tatiana Tennikova, Marika Ruponen, Arto Urtti Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties published pages: 1446-1457, ISSN: 1359-6446, DOI: 10.1016/j.drudis.2019.02.001	Drug Discovery Today 24/8	2020-04-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EYETREAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EYETREAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)